Castle Biosciences (CSTL)

• Market cap: $1.13B
• 1 day: 1.74%
• 5 days: -1.43%
• 1 month: 10.94%
• 3 months: 80.35%
• 6 months: 105.26%
• Year to date: 37.77%
• 1 year: 32.66%
• 5 years: -37.61%
• 10 years: 80.51%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Employees: 823